Cargando…
Antibody evasion by the P.1 strain of SARS-CoV-2
Terminating the SARS-CoV-2 pandemic relies upon pan-global vaccination. Current vaccines elicit neutralizing antibody responses to the virus spike derived from early isolates. However, new strains have emerged with multiple mutations, including P.1 from Brazil, B.1.351 from South Africa, and B.1.1.7...
Ejemplares similares
-
Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera
por: Zhou, Daming, et al.
Publicado: (2021) -
Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum
por: Liu, Chang, et al.
Publicado: (2021) -
Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera
por: Supasa, Piyada, et al.
Publicado: (2021) -
Potent cross-reactive antibodies following Omicron breakthrough in vaccinees
por: Nutalai, Rungtiwa, et al.
Publicado: (2022) -
The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants
por: Liu, Chang, et al.
Publicado: (2022)